Cargando…
Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulati...
Autores principales: | Martinez-Bosch, Neus, Barranco, Luis E., Orozco, Carlos A., Moreno, Mireia, Visa, Laura, Iglesias, Mar, Oldfield, Lucy, Neoptolemos, John P., Greenhalf, William, Earl, Julie, Carrato, Alfredo, Costello, Eithne, Navarro, Pilar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152472/ https://www.ncbi.nlm.nih.gov/pubmed/30250644 http://dx.doi.org/10.18632/oncotarget.26034 |
Ejemplares similares
-
The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer
por: Manero-Rupérez, Noemí, et al.
Publicado: (2020) -
Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis
por: Martínez-Bosch, Neus, et al.
Publicado: (2021) -
S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes
por: Nedjadi, Taoufik, et al.
Publicado: (2018) -
Where the metabolome meets the microbiome for pancreatic cancer detection
por: Oldfield, Lucy, et al.
Publicado: (2023) -
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)